India's ongoing efforts to tighten clinical trial regulations have stirred controversy among researchers around the globe, and now the world's largest CRO has shuttered one of its facilities in the country, citing a tough regulatory climate.
U.K.-based CDMO Aesica Pharmaceuticals said it has struck a deal with CMIC Holdings, a contract manufacturer and drug developer that has operations in Japan, to help each other's clients there, as well as in Europe and the U.S.
The prospect of GlaxoSmithKline's malaria vaccine arriving in the next two years has raised hopes for preventing disease in Africa, but more work is needed in other areas. This week brought hope a vaccine can tackle hookworm, but also news that cost is limiting the impact of a vaccine against rabies that could prevent 24,000 deaths a year.
GlaxoSmithKline's former China chief, absent from the country when bribery allegations surfaced this summer, returned in late July to cooperate with investigators. Now, The Telegraph reports that Mark Reilly is no longer on the scene voluntarily. Chinese authorities have barred him from leaving the country, the U.K. newspaper reports.
Eli Lilly has signed on to collaborate on fruquintinib, committing to a package of $86.5 million in fees and milestones to partner on a tumor treatment which was put up on the deal table earlier this year.
CardioKinetix hit another big milestone recently with news that the California company's heart failure treatment device has been successfully implanted into two patients in China. Asia is a pivotal part of the world for medical device companies right now, and China is the brass ring.
Catalent has snapped up a Brazilian contract manufacturer, expanding its hold on the global softgel market by growing its presence in Latin America.
Noting that Japan is one of the world's fastest-growing pharmaceutical markets, Marc Dunoyer, AstraZeneca's executive vice president of global products and portfolio strategy said: "This deal is a strong strategic fit for AstraZeneca, reinforcing both our focus on oncology as a core therapy area and Japan as one of our key growth drivers."
It seemed like a match made in heaven. A few years ago, as the patent cliff neared and drugmakers were looking for new sources of revenue, market researchers were toting up growth prospects around...
The emergence of Indian vaccine manufacturers has helped health authorities drive down the cost of immunization campaigns. Now, the downwards trend is set to accelerate. China has entered the global vaccine arena.